Radioligand Therapy (RLT) in Neuroendocrine Neoplasms
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 220
Special Issue Editor
Special Issue Information
Dear Colleagues,
The treatment methods for neuroendocrine neoplasms (NENs) have been rapidly advancing in recent years. New treatment models now include the use of radioligand therapy (RLT) as an earlier line of treatment. The use of radiopharmaceuticals introduces new possibilities for patients, extending their progression-free survival and overall survival compared to other therapies.
In light of this, we would like to extend an invitation to all researchers working in the field of neuroendocrine neoplasms and radioligand therapies to contribute to a Special Issue of Cancers entitled "Radioligand Therapy (RLT) in Neuroendocrine Neoplasms". We hope that you will share your experiences and study results with us. In addition to original articles, comprehensive reviews are also welcomed.
We anticipate that the deadline of 31 October 2024, will be acceptable for all contributors and provide sufficient time for the preparation of high-value publications.
Prof. Dr. Grzegorz Kamiński
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroendocrine neoplasms (NENs)
- neuroendocrine tumors (NETs)
- radioligand therapy (RLT)
- peptide receptor radionuclide therapy (PRRT)